相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis
Charat Thongprayoon et al.
ARCHIVES OF OSTEOPOROSIS (2019)
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
Noopur Raje et al.
LANCET ONCOLOGY (2018)
Osteoporosis and ischemic cardiovascular disease
Michel Laroche et al.
JOINT BONE SPINE (2017)
Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review
Roy O. Mathew et al.
KIDNEY INTERNATIONAL (2017)
Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based metaanalysis involving 26,442 participants
Lena Tschiderer et al.
PLOS ONE (2017)
Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease A Systematic Review and Meta-analysis
Lisa M. Wilson et al.
ANNALS OF INTERNAL MEDICINE (2017)
Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
Mutsushi Yamasaki et al.
International Journal of Clinical Oncology (2016)
The function and meaning of receptor activator of NF-κB ligand in arterial calcification
Bin Nie et al.
JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES (2015)
Osteoporosis Is Associated With High Risk for Coronary Heart Disease A Population-Based Cohort Study
Sy-Jou Chen et al.
MEDICINE (2015)
RANKL-OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy
Agbor Ndip et al.
DIABETOLOGIA (2014)
RANKL Inhibition With Denosumab Does Not Influence 3-Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk
Elizabeth J. Samelson et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
The three-year incidence of fracture in chronic kidney disease
Kyla L. Naylor et al.
KIDNEY INTERNATIONAL (2014)
Correlation between osteoporosis and cardiovascular disease
Delia Sprini et al.
CLINICAL CASES IN MINERAL AND BONE METABOLISM (2014)
Renal Safety in Patients Treated With Bisphosphonates for Osteoporosis: A Review
Paul D. Miller et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Vascular calcification: pathophysiology and clinical implications
Marcel Liberman et al.
EINSTEIN-SAO PAULO (2013)
Denosumab: mechanism of action and clinical outcomes
D. A. Hanley et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
Efficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with Advanced Cancer
Takayasu Kurata et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2012)
Osteoporosis-a risk factor for cardiovascular disease?
Christos E. Lampropoulos et al.
NATURE REVIEWS RHEUMATOLOGY (2012)
The mechanism of vascular calcification - a systematic review
Wojciech Karwowski et al.
MEDICAL SCIENCE MONITOR (2012)
Fracture risk assessment in patients with chronic kidney disease
S. A. Jamal et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
N. Freemantle et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Effects of Denosumab on Fracture and Bone Mineral Density by Level of Kidney Function
Sophie A. Jamal et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate
D. L. Kendler et al.
OSTEOPOROSIS INTERNATIONAL (2011)
The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts
Anna Enjuanes et al.
ENDOCRINE (2010)
Inhibition of Receptor Activator of NF-κB Ligand by Denosumab Attenuates Vascular Calcium Deposition in Mice
Susann Helas et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research
Peter C. Austin
COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION (2009)
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Functions of RANKL/RANK/OPG in bone modeling and remodeling
Brendan F. Boyce et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2008)
Receptor activator of nuclear factor kappa B ligand and osteoprotegerin regulation of bone remodeling in health and disease
Ann E. Kearns et al.
ENDOCRINE REVIEWS (2008)
Soluble receptor activator of nuclear factor-κB ligand and risk for cardiovascular disease
Stefan Kiechl et al.
CIRCULATION (2007)
Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: Impact of these parameters on early clinical development
Mary Ann Mascelli et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Vascular calcification and osteoporosis-from clinical observation towards molecular understanding
L. C. Hofbauer et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Enhanced T-cell expression of RANK ligand in acute coronary syndrome -: Possible role in plaque destabilization
WJ Sandberg et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction
A Crisafulli et al.
CLINICAL SCIENCE (2005)
Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin
P Collin-Osdoby
CIRCULATION RESEARCH (2004)
Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease
S Kiechl et al.
CIRCULATION (2004)
Toxic acute tubular necrosis following treatment with zoledronate (Zometa)
GS Markowitz et al.
KIDNEY INTERNATIONAL (2003)
Taiwan's new national health insurance program: Genesis and experience so far
TM Cheng
HEALTH AFFAIRS (2003)
分享论文
